This week, there are 9 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - SANTARUS INC's GLUMETZA, containing active ingredient METFORMIN HYDROCHLORIDE - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - INCYTE CORP's JAKAFI, containing active ingredient RUXOLITINIB PHOSPHATE - FRESENIUS KABI USA LLC's SMOFLIPID 20%, containing active ingredient FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - NOVARTIS PHARMACEUTICALS CORP's TASIGNA, containing active ingredient NILOTINIB HYDROCHLORIDE - NOVEN PHARMACEUTICALS INC's XELSTRYM, containing active ingredient DEXTROAMPHETAMINE - NOBELPHARMA CO LTD's HYFTOR, containing active ingredient SIROLIMUS - NOVARTIS PHARMACEUTICALS CORP's LOCAMETZ, containing active ingredient GALLIUM GA-68 GOZETOTIDE Read More

Ruxolitinib, a groundbreaking product of Incyte Corp, has demonstrated an impressive evolution in the pharmaceutical market. Its strategic journey from a niche treatment for rare diseases to a versatile solution for more common dermatological conditions not only emphasizes the strategic significance Read More

Query Drug：RuxolitinibQuery Time：2024-04-25 09:12:38*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More